HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

SR One fuels HotSpot’s $65M B round to fund allosteric R&D

Hotspot’s $65M series B to propel it into the clinic

Boston’s HotSpot Therapeutics Eyes The Clinic Following $65 Million Series B

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

HotSpot announces $65M Series B, as Nimbus pioneers look to keep up in a crowding field

In the decade since Nimbus Therapeutics built a company around computation and little-known phenomena allosteric regulation, the industry has brimmed with algorithm companies and even a few chasing those same targets. Still, a couple of the old leaders think they can keep an edge.

Getting higher-quality hits out of DNA-encoded libraries

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output.

HotSpot acquires DNA-encoded library firm Macroceutics

HotSpot Therapeutics, a biotech firm that launched last year to develop allosteric inhibitors for autoimmune and metabolic diseases, has acquired Macroceutics, a 5-year-old provider of DNA-encoded library screening technologies.

HotSpot Acquires Macroceutics for focused allosteric library

HotSpot is adding a key piece to its allosteric inhibitor platform through the acquisition of DNA-encoded library company Macroceutics: the technology to make chemical libraries tailored to allosteric, rather than active, sites.

Moving beyond the active site: why allostery is newly in fashion

Allosteric pockets on proteins have long been viewed as promising alternatives to active sites for controlling protein function. The problem has been finding them.

Drug hunters explore allostery’s advantages

After decades of focus on proteins’ active sites, a new crop of biotech firms is shifting attention to proteins’ hidden regulatory pockets

HotSpot debuts with $45m to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. T

HotSpot Therapeutics debuts with $45 million to pursue allosteric inhibitors

HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets.

With $45M, HotSpot Takes Drug Research to New Biological Real Estate

In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines.

Atlas, Sofinnova Bet $45M on ‘HotSpots’

Atlas Venture and Sofinnova Partners co-lead investment in a couple of Nimbus alumni

Hotspot Therapeutics Turns Up The Heat On Natural Allostery

HotSpot is pioneering a new approach to drugging the allosteric sites that Nature itself uses to control proteins.

Float like a butterfly: agility in biotech

In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.

Allostery: Realizing The Promise

With the discovery of the first allosteric inhibitors for bcr-abl that could offer the first clinical cures for CML, allosteric drug discovery is undergoing a resurgence.